ANHL1931- A Randomized Phase 3 trial of Nivolumab (NSC# 748726 IND# 125462) in Combination with Chemo-immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-cell Lymphoma
Details
Age
Child to Adult
Eligibility
Age ≥ 2 years; Patient must have histologically confirmed primary mediastinal B-cell lymphoma (PMBCL) as defined by WHO criteria
Type of Study
Treatment
Locations
Childrens Hospital Colorado
Principal Investigator
Kelly Maloney, MD
Study ID
Protocol Number: 21-4667
More information available at ClinicalTrials.gov: NCT04759586
Categories
Is this Study for You?
Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers